Background: Pemphigus is an autoimmune bullous disease characterized by the presence of antidesmoglein autoantibodies. However, the mechanism of its autoantibody production remains unknown. In previous reports, we have described rare cases of pemphigus and pemphigoid associated with silicosis. It is well known that during long-term silicosis, some autoimmune diseases, such as systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis, can occur. Objective: The aim of this study was to explore the presence of pemphigus or pemphigoid autoantibodies in silicosis patients without clinical bullous diseases or collagen diseases. Method: The presence of pemphigus antibodies was examined in 54 silicosis patients with no associated bullous diseases, using immunofluorescence, the enzyme-linked immunosorbent assay (ELISA) for desmoglein 1 and 3, and immunoblotting methods. In the antibody-positive cases, HLA genotyping of peripheral lymphocytes was performed with PCR-RFLP. Results: Seven out of the 54 patients were found to be positive for pemphigus antibodies and 1 for bullous pemphigoid by immunofluorescence. In addition, by ELISA, 6 patients were found to be positive against the desmoglein 1 antigen, 2 against the desmoglein 3 antigen and 2 against both desmoglein 1 and desmoglein 3. Conclusion: The results of the present study strongly suggest the occurrence of pemphigus and pemphigoid autoantibodies in patients with silicosis. It remains unclear whether such patients will develop an autoimmune bullous disease in the future. Accordingly, long-term follow-up of antibody-positive patients is required.

Keywords:
Pemphigus antibody, Silicosis, Antidesmoglein antibody, Fas antigen, Decoy receptor 3 gene
1.
Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, Shimizu N, Nishikawa T: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997;159:2010–2017.
2.
Amagai M, Hashimoto T, Komai A, Hashimoto K, Kitajima Y, Ohya K, Iwanami H, Nishikawa T: Usefulness of enzyme-linked immunosorbent assay (ELISA) using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999;140:351–357.
3.
Hashimoto T, Amagai M, Garrod DR, Nishikawa T: Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1. Epi Cell Biol 1995;4:63–69.
4.
Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167–170.
5.
Yamagami Y, Kohda M, Mimura S, Ueki H: Pemphigus vulgaris associated with silicosis. Dermatology 1998;197:55–57.
6.
Ueki H, Takao J, Yamasaki F, Yoda N, Yamaguchi M, Kohda M: Pemphigus foliaceus associated with silicosis. Br J Dermatol 2000;143:456–457.
7.
Ueki H, Kohda M, Hashimoto T, Komai A, Nobutoh T, Yamaguchi M, Omori K, Miyashita Y, Yoda N: Bullous pemphigoid associated with silicosis. Dermatology 2000;201:265–267.
8.
Rodnan GP, Benedek TG, Medsger TA Jr, Cammarata RJ: The association of progressive systemic sclerosis (scleroderma) with coal miners’ pneumoconiosis and other forms of silicosis. Ann Intern Med 1967;66:323–334.
9.
Haustein UF, Ziegler V, Herrmann K: Silica induced scleroderma. J Am Acad Dermatol 1990;22:444–448.
10.
Hatron PY, Plouvier B, François M: Association de lupus érythémateux et silicose. Rev Méd Interne 1982;30:8–15.
11.
Cledes J, Hervé JP, Clavier J: Silicose pulmonaire et lupus érythémateux disséminé. Poumon Cœur 1983;39:205–207.
12.
Caplan A: Certain unusual radiological appearance in the chest of coalminers suffering from rheumatoid arthritis. Thorax 1953;8:29–37.
13.
Sanches RJ, Wichmann I, Salaberri J: Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis 1993;52:534–538.
14.
Matsumura K, Hashimoto T, Ohata Y, Nishikawa T: Majority of bullous pemphigoid and herpes gestationis sera react with NC16a domain of the 180 kD bullous pemphigoid antigen. Arch Dermatol Res 1996;288:507–509.
15.
Ishii K, Amagai M, Komai A, Ebihara T, Chorzelski TP, Jablonska S, Ohya K, Nishikawa T, Hashimoto T: Desmoglein 1 and desmoglein 3 are the target autoantigens in herpetiform pemphigus. Arch Dermatol 1999;135:943–947.
16.
Moribe T, Kaneshige T, Hirakata M, Momori T, Akizuki M, Inoko H: Identification of a DRB1*0405 variant (DRB1*04052) using the PCR-RFLP method. Tissue Antigens 1996;47:450–453.
17.
Senger DPS, Goldstein R: Comprehensive typing of DQB1 alleles by PCR-RFLP. Tissue Antigens 1994;43:242–248.
18.
Akaza T, Imanishi T, Fujiwara K, Tokunaga K, Yashiki S, Fujiyoshi T, Sonoda S, Tuji T: HLA alleles and haplotypes of Japanese population. MHC IRS Suppl 1994;1:219–226.
19.
Beutner EH, Jordon RE, Chorzelski TP: The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol 1968;51:63–80.
20.
Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T: Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vitro in neonatal mice. J Clin Invest 1998;102:775–782.
21.
Anhalt GJ, Kim S, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H, Mutasim D, Ariss AL, Labib RS: Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasma. N Engl J Med 1990;323:1729–1735.
22.
Anhalt GJ: Paraneoplastic pemphigus. Adv Dermatol 1997;12:77–97.
23.
Pisani M, Ruocco V: Drug induced pemphigus. Clin Dermatol 1986;4:118–132.
24.
Civatte J: Drug-induced pemphigus: Clinical review and pathogenic mechanism. Bull Acad Natl Med 1986;170:1057–1063.
25.
Bhol K, Yunis J, Ahmed AR: Pemphigus vulgaris in distant relatives of two families: Association with major histocompatibility complex class II genes. Clin Exp Dermatol 1996;21:100–103.
26.
Mohimen A, Narula M, Ruocco V, Pisani M, Ahmed AR: Presence of autoantibody in healthy relatives of Italian patients with pemphigus vulgaris. Arch Dermatol Res 1993;285:176–177.
27.
Brandsen R, Frusic-Zlotkin M, Lyubimov H, Yunes F, Michel B, Tamir A, Milner Y, Brenner S: Circulating pemphigus IgG in families of patients with pemphigus: Comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. J Am Acad Dermatol 1997;36:44–52.
28.
Ahmed AR, Mohimen A, Yunis AJ, Nadeem MM, Kumar V, Beutner EH, Alper CA: Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993;177:419–424.
29.
Warren SJP, Lin M-S, Giudice GJ, Hoffmann RG, Hans-Filho G, Aoki V, Rivitti EA, dos Santos V, Diaz LA: The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. N Engl J Med 2000;343:23–30.
30.
Chan LS. Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB: Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol 1998;110:103–109.
31.
Miyagawa S, Higashimine I, Iida T, Yamashina Y, Fukumoto T, Shirai T: HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese. J Invest Dermatol 1997;109:615–618.
32.
Miyagawa S, Amagai M, Niizeki H, Yamashina Y, Kaneshige T, Nishikawa T, Shirai T, Inoko H: HLA-DRB1 polymorphisms and autoimmune responses to desmogleins in Japanese patients with pemphigus. Tissue Antigens 1999;54:333–340.
33.
Ueki A, Yamaguchi M, Ueki H, Watanabe Y, Ohsawa G, Kinugawa K, Kawakami Y, Hyodoh F: Polyclonal human T-cell activation by silicate in vitro. Immunology 1994;82:332–335.
34.
Aikoh T, Tomokuni A, Matsukii T, Hyodoh F, Ueki H, Otsuki T, Ueki A: Activation-induced cell death in human peripheral blood lymphocytes after stimulation with silicate in vitro. Int J Oncol 1998;12:1355–1359.
35.
Tomokuni A, Aikoh T, Matsukii T, Isozaki Y, Otsuki T, Kita S, Ueki H, Kusaka M, Kishimoto T, Ueki A: Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 1997;110:303–309.
36.
Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsukii Y, Isozaki Y, Hyodoh F, Ueki H, Kusaka M, Ueki A: Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol 2000;119:323–327.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.